spinal muscular atrophy News

Nutrition Basics: Fostering Health and Growth for Spinal Muscular Atrophy is Families of SMA’s newest release of the SMA Care Series Booklets, which are provided free of charge to all SMA families, as well as SMA Care Providers worldwide.

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

Dream Room Makeovers, Inc with Stylish Stagers, Inc. to Remodel Union, NJ Home in One Day!

Awards to help develop new therapies for SMA. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year.

Mama Bracelets' owners launch SMA Awareness bracelets in efforts to fund research to cure SMA as their daughter has been recently diagnosed with SMA Type 2.

The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively.

Boynton Beach residents Shaina and Adi Rappoport have served as the event organizers since 2002 when their son, Jacob, passed way from SMA (Spinal Muscular Atrophy) related complications. Jacob was nine months old.

As 2010 comes to a close, we wanted to thank you for your donations and efforts that have supported our research programs and family services.

In response to our October Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy we received nine Letters of Intent for potential programs.

The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA. FSMA began the Quinazoline, or DcpS inhibitor RG3039, program in 2000.

A boy suffering from spinal muscular atrophy has his wish to visit the Florida theme parks granted through national children’s charity Kids Wish Network.

Families of SMA announces Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy. FSMA is aiming to fund two new preclinical drug development programs in 2011, with more to follow.

All across the United States volunteers will come together to raise funds for critical SMA research and patient support programs.

Richmond-based FightSMA announced today a new fundraising campaign for spinal muscular atrophy gene therapy, “Realizing the Dream.”

A nonprofit dedicated to developing a treatment for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research grant to Dr. Brian Kaspa of The Ohio State University.

Thousands are using Tweet for a Cure to voice their support for Spinal Muscular Atrophy (SMA) research.

Fight SMA Publishes Web Video from 2009 Spinal Muscular Atrophy Conference

Fight SMA is celebrating another successful annual conference.

Fight SMA is providing a free live webcast of two seminars from this year’s Family and Friends Annual Spinal Muscular Atrophy Conference in Washington D.C.

One of the exciting items in an upcoming charity auction for Fight SMA (http://www.fightsma.org) is an incredibly hard-to-find set of six box seats to the Kentucky Derby. Absentee bidding is available!

An update of an earlier story about the Fight SMA Spinal Muscular Atrophy National Conference, held April 22-27 in Washington D.C.

Families from all over the nation are traveling to the nation’s capital for the the twelfth Fight SMA Annual Conference, with a goal of advancing the fight against the deadly disease spinal muscular atrophy (SMA).

Fight SMA (http://www.fightsma.org), has launched the first podcast to focus on inspirational stories about people fighting spinal muscular atrophy (SMA), the leading genetic killer of children under two.